Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy

Annals of Surgical Oncology

Volumn 12, Issue 8, 2005, Pages 587-596

  Pawlik, Timothy M ^a   Ross, Merrick I ^a   Johnson, Marcella M ^b   Schacherer, Christopher W ^a   McClain, Dana M ^a   Mansfield, Paul F ^a   Lee, Jeffrey E ^a   Cormier, Janice N ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

In transit; Lymph node; Melanoma; Recurrence; Sentinel lymph node biopsy

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; LIMB TUMOR; LYMPHADENECTOMY; MALE; MELANOMA; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOLOGY; PREDICTION; SCHOOL CHILD; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM SEEDING; PROGNOSIS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 23744460937     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2005.05.025     Document Type: Article

References (38)

1. Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999;6:315-21.
2. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science 2002;296:1811-2.
3. Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986;12:175-80.
4. Attie JN, Khafif RA. Melanotic Tumors - Biology, Pathology and Clinical Features. Springfield, IL: Charles C. Thomas, 1964.
5. Karakousis CP, Choe KJ, Holyoke ED. Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet 1980;150:29-32.
6. Yu LL, Heenan PJ. The morphological features of locally recurrent melanoma and cutaneous metastases of melanoma. Hum Pathol 1999;30:551-5.
7. Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004;30:244-7.
8. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003;10:575-81.
9. Gershenwald JE, Prieto VG, Colome-Grimmer MI, et al. The prognostic significance of microscopic tumor burden in 945 melanoma patients undergoing sentinel lymph node biopsy (abstract). Proc Am Soc Clin Oncol 2000;19:2169.
10. Lemeshow S, Hosmer D. Applied Logistic Regression. New York: Wiley, 2000.
11. Nakayama T, Taback B, Turner R, Morton DL, Hoon DS. Molecular clonality of in-transit melanoma metastasis. Am J Pathol 2001;158:1371-8.
12. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003;10: 569-74.
13. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151-6.
14. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-9.
15. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996;3:446-52.
16. Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000;88:1063-71.
17. Estourgie SH, Nieweg OE, Valdes Olmos RA, Hoefnagel CA, Kroon BB. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol 2003;10:681-8.
18. Estourgie SH, Nieweg OE, Kroon BB. High incidence of intransit metastases after sentinel node biopsy in melanoma. In: Estourgie SH (eds). Clinical Relevance and Refinement of the Sentinel Node Procedure in Breast Cancer and Melanoma. Amsterdam: Drukkerij Verhaag, 2004:91-4.
19. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002.
20. Cruse CW, Wells KE, Schroer KR, Reintgen DS. Etiology and prognosis of local recurrence in malignant melanoma of the skin. Ann Plast Surg 1992;28:26-8.
21. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94-8.
22. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cancer 1997;80:1418-25.
23. Kretschmer L, Preusser KP, Neumann C. Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impact. Melanoma Res 2002;12:499-504.
24. Heenan PJ. Local recurrence of melanoma. Australas J Dermatol 1997;38:S59-S62.
25. Ackerman AB, Cerroni L, Kerl H. Pitfalls in Histopathologic Diagnosis of Malignant Melanoma. Philadelphia: Lea & Febiger, 1994.
26. Garbe C, Cerroni L, Kerl H. Melanozytaere naevi und malignes melanom. In: Kerl H, Garbe C, Cerroni L (eds). Histopathologie der Haut. Berlin: Springer, 2003: 593-649.
27. Singletary SE, Tucker SL, Boddie AW Jr. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 1988;61:1437-40.
28. Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. J Surg Oncol 1990;44:146-50.
29. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149:17-21.
30. Rampen FH, van Andel JG. Female sex is a risk factor for satellite and in-transit recurrences from cutaneous melanoma. Eur J Cancer Clin Oncol 1984;20:1151-3.
31. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5.
32. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.
33. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906-12.
34. Day CL Jr, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981;194:108-12.
35. Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991;126:1461-8.
36. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55:1398-402.
37. Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8:771-8.
38. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983;1:126-34.